Overview

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 300 patients will be enrolled.
Phase:
Phase 3
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.